UBS Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-193,555
| Closed | -$2.89M | – | 11552 |
|
|
2022
Q4 | $2.89M | Buy |
193,555
+191,896
| +11,567% | +$2.66M | ﹤0.01% | 3013 |
|
|
2022
Q3 | $13K | Sell |
1,659
-502
| -23% | -$3.86K | ﹤0.01% | 8126 |
|
|
2022
Q2 | $14K | Sell |
2,161
-3,293
| -60% | -$15.9K | ﹤0.01% | 7475 |
|
|
2022
Q1 | $31K | Sell |
5,454
-1,226
| -18% | -$5.05K | ﹤0.01% | 6984 |
|
|
2021
Q4 | $31K | Buy |
6,680
+6,480
| +3,240% | +$40.2K | ﹤0.01% | 7388 |
|
|
2021
Q3 | $1K | Hold |
200
| – | – | ﹤0.01% | 9446 |
|
|
2021
Q2 | $1K | Sell |
200
-916
| -82% | -$6.32K | ﹤0.01% | 9325 |
|
|
2021
Q1 | $9K | Sell |
1,116
-5,589
| -83% | -$48.2K | ﹤0.01% | 8061 |
|
|
2020
Q4 | $39K | Buy |
6,705
+5,988
| +835% | +$34.3K | ﹤0.01% | 6412 |
|
|
2020
Q3 | $4K | Sell |
717
-4,324
| -86% | -$21.4K | ﹤0.01% | 7493 |
|
|
2020
Q2 | $26K | Buy |
5,041
+4,530
| +886% | +$28.6K | ﹤0.01% | 6394 |
|
|
2020
Q1 | $2K | Sell |
511
-2,818
| -85% | -$14K | ﹤0.01% | 7708 |
|
|
2019
Q4 | $21K | Buy |
3,329
+1,476
| +80% | +$10.9K | ﹤0.01% | 6867 |
|
|
2019
Q3 | $16K | Buy |
1,853
+1,629
| +727% | +$12.1K | ﹤0.01% | 6898 |
|
|
2019
Q2 | $1K | Buy |
224
+24
| +12% | +$206 | ﹤0.01% | 7792 |
|
|
2019
Q1 | $2K | Sell |
200
-5,084
| -96% | -$52.5K | ﹤0.01% | 7496 |
|
|
2018
Q4 | $84K | Sell |
5,284
-2,571
| -33% | -$56.6K | ﹤0.01% | 5690 |
|
|
2018
Q3 | $260K | Buy |
7,855
+2,121
| +37% | +$54.5K | ﹤0.01% | 4859 |
|
|
2018
Q2 | $129K | Buy |
5,734
+5,724
| +57,240% | +$136K | ﹤0.01% | 5265 |
|
|
2018
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 8380 |
|
|
2017
Q4 | $0 | Sell |
10
-1,558
| -99% | -$48.4K | ﹤0.01% | 8255 |
|
|
2017
Q3 | $57K | Buy |
1,568
+1,558
| +15,580% | +$48.2K | ﹤0.01% | 5706 |
|
|
2017
Q2 | $0 | Sell |
10
-112
| -92% | -$882 | ﹤0.01% | 8187 |
|
|
2017
Q1 | $1K | Buy |
122
+99
| +430% | +$715 | ﹤0.01% | 7510 |
|
|
2016
Q4 | $0 | Sell |
23
-19
| -45% | -$127 | ﹤0.01% | 8200 |
|
|
2016
Q3 | $0 | Sell |
42
-961
| -96% | -$9.05K | ﹤0.01% | 8098 |
|
|
2016
Q2 | $10K | Buy |
1,003
+943
| +1,572% | +$9.09K | ﹤0.01% | 6809 |
|
|
2016
Q1 | $1K | Sell |
60
-1,158
| -95% | -$11.5K | ﹤0.01% | 7499 |
|
|
2015
Q4 | $16K | Sell |
1,218
-489
| -29% | -$5.81K | ﹤0.01% | 6971 |
|
|
2015
Q3 | $21K | Buy |
1,707
+894
| +110% | +$12.9K | ﹤0.01% | 6662 |
|
|
2015
Q2 | $14K | Buy |
813
+484
| +147% | +$8.71K | ﹤0.01% | 7212 |
|
|
2015
Q1 | $4K | Sell |
329
-2,873
| -90% | -$31.4K | ﹤0.01% | 8255 |
|
|
2014
Q4 | $27K | Buy |
+3,202
| New | +$29.3K | ﹤0.01% | 7245 |
|
UBS Group's AVEO Position: Q1 2023 in Review
UBS Group sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 193,555 shares — an estimated $2.89M sold.
UBS Group first reported a position in AVEO in Q4 2014 and held it in 33 quarters. The position peaked at $2.89M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- UBS Group reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 193,555 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.89M.
- UBS Group first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2014 and held it in 33 quarters.
- UBS Group's AVEO Pharmaceuticals, Inc. position peaked at $2.89M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.